Drugs / SLx-2101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00562549 | Jul → Dec 2007 | hypertensive disorder | Retension Pharmaceuticals. Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00562614 | Jun → Dec 2007 | hypertensive disorder | Retension Pharmaceuticals. Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00528242 | Jun 2007 → Mar 2008 | Raynaud disease | Response Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLx-2101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00562614 ↗ |
| Route | Oral | “Repeat Oral Doses of SLx-2101 Once Daily” NCT00528242 ↗ |